HCA Healthcare, Inc. (HCA) $471.84
HCA Healthcare finds itself at a critical juncture, with its stock price plummeting into deeply oversold conditions that historically precede significant bounces.
52-wk High $556.52
📌 Investment Snapshot
- 💰 HCA trades at $471.84, commanding a $105.5B market cap with a 16.7x P/E.
- 📈 Latest quarter revenue hit $19.51B, delivering robust $8.09 EPS.
- 🔑 Aggressive share buybacks and extreme oversold RSI signal a potential rebound.
- 🎯 Analysts maintain a Buy consensus with a $543.05 target, implying 15.1% upside.
HCA’s stock has entered severely oversold territory, with its RSI flashing a rare 10.1 reading. This technical setup, coupled with strong institutional support and ongoing share buybacks, presents a compelling entry point.
| 📍 Entry Zone | $469 or below | 🛑 Stop-Loss | $445 |
| 📋 Adjust If | Price reclaims $480 on above-average volume. | ||
The Investment Case — Why Now?
HCA Healthcare’s stock has experienced a sharp correction over the past month, shedding over 11% of its value and pushing its Relative Strength Index to an extreme 10.1. This significant pullback has brought the stock to a crucial support confluence around its Volume Profile Point of Control (VP POC) and the 200-day Simple Moving Average, creating a high-conviction dip opportunity. The company’s consistent revenue and EPS growth, alongside substantial share buybacks, underpin a strong fundamental case for recovery.
The primary risk to this thesis lies in a sustained breakdown below the $445 level, which would invalidate the 200-day SMA support and signal a deeper capitulation. Furthermore, rising interest rates could pressure healthcare facility expansion plans and increase borrowing costs, potentially dampening future growth prospects.
🤔 Given HCA’s strong fundamentals and aggressive buyback program, does the current technical weakness represent a genuine value opportunity or a sign of deeper underlying issues?
🏢 Company Overview
| Detail | Value |
|---|---|
| Company | HCA Healthcare, Inc. |
| Ticker / Exchange | HCA / NYSE |
| Sector / Industry | Healthcare / Medical Care Facilities |
| CEO | Samuel N. Hazen |
| Founded / HQ | 1968 / Nashville, Tennessee |
📈 Price Action & Technicals
Inside VA
Recent sell-side sweeps at $546.62 and $545.24 suggest institutional distribution into strength, while a buy-side sweep at $522.32 indicates some accumulation.
HCA’s price action reveals a significant downtrend over the past month, with the stock currently trading well below its 50-day SMA of $509.14. However, it finds strong support above the critical 200-day SMA at $446.65 and the Volume Profile Point of Control (VP POC) at $469.33. This confluence of technical levels suggests a potential floor for the recent selling pressure.
The Relative Strength Index (RSI) at 10.1 screams oversold, a level rarely sustained and often preceding a sharp rebound. While the MACD confirms bearish momentum with a negative reading and a signal line cross, the extreme RSI suggests this downtrend may be nearing exhaustion. The ADX reading of 41.5, with a dominant -DI, underscores the strength of the current bearish trend, but also highlights its maturity.
The stock trades above its Anchored VWAP from April 2025 at $426.26, indicating that longer-term participants who entered around that time are still in profit. Its position just above the Volume Profile Point of Control ($469.33) suggests strong price acceptance at this level, potentially acting as a springboard for a recovery. The Technical Confluence Score of 70/100, driven by positive VWAP and VP signals, further supports this outlook.
Volume is running below average at 0.84x, which could imply a lack of conviction behind the recent sell-off, or simply reduced participation. The price is currently within the lower Bollinger Band, confirming the oversold condition. Three recent sell-side liquidity sweeps at higher prices indicate institutional selling, but the single buy-side sweep suggests some buyers are stepping in at lower levels.
Historically, such extreme RSI readings in fundamentally sound companies often lead to a mean reversion bounce within the subsequent 1-3 months. A similar pattern in late 2023 saw HCA recover over 10% from comparable oversold levels.
🤔 With the RSI at such extreme lows, are you prepared to capitalize on a potential mean reversion, or does the strong bearish trend indicated by ADX warrant further caution?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| HCA | HCA Healthcare, Inc. | 16.7x |
| UHS | Universal Health Services | 17.0x |
| LH | LabCorp | 16.0x |
| TENET | Tenet Healthcare | 11.0x |
| S&P 500 | Index Average | 21.0x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $19.51B | $8.09 | +5.5% |
| Q3 2025 | $19.16B | $6.96 | +5.0% |
| Q2 2025 | $18.61B | $6.83 | +4.5% |
| Q1 2025 | $18.32B | $6.45 | +4.0% |
HCA demonstrates robust capital allocation, generating $0.9B in Free Cash Flow in the latest quarter. The company actively returns capital to shareholders, executing $2.6B in share buybacks during the same period, significantly boosting shareholder value.
🚀 Growth Drivers — What Moves the Stock
- Demographic Tailwinds 🟢 Upside Surprise — The aging U.S. population and increasing demand for healthcare services provide a structural growth driver for HCA’s extensive network of hospitals and facilities. This trend ensures a consistent patient base and revenue stream.
- Strategic Acquisitions & Expansion 🟡 Priced In — HCA consistently pursues strategic acquisitions and facility expansions, enhancing its market presence and service offerings. This inorganic growth strategy complements organic patient volume increases, driving top-line expansion.
- Operational Efficiency & Cost Management 🟡 Priced In — The company’s focus on operational efficiencies and disciplined cost management allows for margin expansion even in a challenging labor and supply chain environment. This commitment to profitability directly translates to stronger EPS.
🤔 With demographic tailwinds largely priced in, how much incremental growth can HCA extract from strategic acquisitions and operational efficiencies in the current economic climate?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 14,716 |
| Blackrock Inc. | 12,581 |
| Sanders Capital, LLC | 10,464 |
| State Street Corporation | 7,566 |
| Capital World Investors | 4,999 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| MCALEVEY MICHAEL R. | Officer | Feb 18, 2026 | Grant | 1,694 |
| MCALEVEY MICHAEL R. | Officer | Feb 13, 2026 | Grant | 5,000 |
| BERRES JENNIFER | Officer | Feb 11, 2026 | Grant | 8,020 |
| WYATT CHRISTOPHER F | Officer | Feb 11, 2026 | Grant | 4,000 |
| WYATT CHRISTOPHER F | Officer | Feb 10, 2026 | Grant | 3,350 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 3.1 |
⚠ Key Risk Factors
~$0.50 EPS hit
~3% revenue hit
~5% patient volume decline
~1% market share erosion
🤔 How resilient are HCA’s margins to sustained inflationary pressures on labor and supplies, and what is management’s contingency plan for potential reimbursement cuts?
🎯 Guidance & Wall Street View
Management has consistently provided stable to positive guidance, emphasizing continued investment in facilities and technology to support long-term growth. They project sustained demand for healthcare services.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $635.0 | $543.05 | $425.0 | 21 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| TD Cowen | Buy | $570 | Mar 2026 | Maintains |
| Mizuho | Outperform | $550 | Feb 2026 | Maintains |
| UBS | Buy | $560 | Feb 2026 | Maintains |
| JP Morgan | Neutral | $500 | Feb 2026 | Maintains |
| Argus Research | Buy | $580 | Feb 2026 | Maintains |
The strong analyst consensus for a Buy rating and a 15.1% upside potential to the mean target of $543.05 underscores Wall Street’s confidence in HCA’s long-term prospects, despite recent price weakness. Even the lowest target of $425.0 suggests limited downside from current levels.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- A sharp rebound from extreme oversold RSI (10.1) drives price back towards the 50-day SMA ($509) and fills the unfilled bearish FVGs.
- Strong Q1 2026 earnings (next earnings July 15) beat expectations, fueled by robust patient volumes and effective cost management, leading to upward revisions in guidance.
📊 Base Case
HCA stabilizes around the current VP POC and 200-day SMA, experiencing a modest bounce as institutional buyers step in to defend key technical levels. Growth drivers remain intact, but macroeconomic headwinds limit aggressive upside. Fair value is derived from a blend of analyst targets and historical P/E multiples.
🐻 Bear Case
- Price breaks below the 200-day SMA ($446.65) and the low analyst target ($425), triggering further technical selling and stop-loss cascades.
- Unexpected negative regulatory changes or a significant miss on Q1 earnings guidance leads to a re-rating of the stock’s growth prospects.
🎯 Investor Action Plan — By Profile
Initiate a short-term long position at $469 or below, targeting the first unfilled FVG at $476.75, with a tight stop-loss below $465. This plays the oversold bounce.
Scale into a core position between $465 and $470, leveraging the strong support at the VP POC and 200-day SMA. Plan to add on any confirmed break above $480.
For existing positions, maintain holdings given the company’s robust fundamentals and long-term demographic tailwinds. Consider adding on significant dips towards the $425-$440 range if the technical picture deteriorates further.
❓ Investor FAQ — People Also Ask
Q: Why is HCA’s stock price falling despite strong earnings?
HCA’s recent price decline appears to be driven by technical factors and broader market sentiment rather than fundamental weakness. The stock’s RSI has plunged to 10.1, indicating an extreme oversold condition, suggesting the sell-off may be overdone.
Q: What are the key support levels for HCA right now?
HCA finds immediate support at its Volume Profile Point of Control (VP POC) around $469.33 and the 200-day Simple Moving Average at $446.65. These levels are crucial for a potential rebound.
Q: Is HCA’s dividend yield attractive for income investors?
With a dividend yield of 0.66%, HCA is not primarily an income play. However, the company’s consistent Free Cash Flow and significant share buybacks ($2.6B latest Q) indicate a strong commitment to returning capital to shareholders, albeit through capital appreciation rather than high dividends.
📊 Want to check the current price action yourself?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The views expressed herein are those of the author and do not necessarily reflect the views of Goldman Sachs or its affiliates.
All active positions and their real-time performance are tracked on our Investment Log.
#HCA #HCAHealthcare #HealthcareStocks #StockAnalysis #Oversold #BuyTheDip #USStocks #Veqtio